Terrence Bradley

Updated protocol: IMPROVEMF, a phase 1b trial of imetelstat (IME)+ ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1/2 or high-risk (HR) myelofibrosis (MF).

John Mascarenhas, Andrew Tucker Kuykendall, Terrence Bradley, Bart L Scott et autres

TPS6604 Background: In preclinical evaluations, sequential treatment (tx) with RUX, a Janus kinase inhibitor (JAKi), and IME, a telomerase inhibitor, selectively reduced MF hematopoietic stem cells (HSC) and progenitor cells. In the Phase 2 IMbark trial (NCT02426086), IME monotherapy showed clinical activity …

us (code pays fourni par la source)

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib

Pankit Vachhani, Abdulraheem Yacoub, Raajit K. Rampal, Terrence Bradley et autres

Most myelofibrosis (MF) patients treated with ruxolitinib fail to achieve optimal response (i.e., spleen volume reduction ≥35% [SVR35] and improvement in total symptom score ≥50% [TSS50], and instead experience suboptimal reductions in spleen volume and constitutional symptoms. Maximizing SVR and TSS is …

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib

Pankit J. Vachhani, Abdulraheem Yacoub, Raajit K. Rampal, Terrence Bradley et autres

Most myelofibrosis (MF) patients treated with ruxolitinib fail to achieve optimal response (i.e., spleen volume reduction ≥35% [SVR35] and improvement in total symptom score ≥50% [TSS50], and instead experience suboptimal reductions in spleen volume and constitutional symptoms. Maximizing SVR and TSS is …

us, gb, it, de (code pays fourni par la source)

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib

Pankit Vachhani, Abdulraheem Yacoub, Raajit K. Rampal, Terrence Bradley et autres

Most myelofibrosis (MF) patients treated with ruxolitinib fail to achieve optimal response (i.e., spleen volume reduction ≥35% [SVR35] and improvement in total symptom score ≥50% [TSS50], and instead experience suboptimal reductions in spleen volume and constitutional symptoms. Maximizing SVR and TSS is …

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy

Justin M. Watts, Ellen Cvejanovich Madarang, Diana Abbott, Payton Hart et autres

Venetoclax (ven) + azacitidine (aza) is the standard of care for newly-diagnosed acute myeloid leukemia (AML) patients who are not candidates for intensive chemotherapy (IC). Because prognostic factors for ven/aza and IC differ, an AML patient fit for IC may derive more …

us (code pays fourni par la source)

Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis

John O Mascarenhas, Andrew Tucker Kuykendall, Terrence Bradley, Bart Lee Scott et autres

Abstract Introduction: Myelofibrosis (MF) is a type of myeloproliferative neoplasm characterized by ineffective hematopoiesis, aberrant expression of inflammatory cytokines, and bone marrow fibrosis. JAK inhibitors (JAKi) block the JAK/STAT-signaling pathway that is dysregulated in patients with MF, resulting in relief of splenomegaly …

us, Afrique du Sud (code pays fourni par la source)

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Andrew Jonas, Sangeetha Venugopal, George Yaghmour, Manu Raj Pandey et autres

Abstract Background: Outcomes for relapsed or refractory (R/R) acute myeloid leukemia (AML) remain poor despite advances in the treatment of AML. MEC, consisting of mitoxantrone, etoposide (ETOP), and cytarabine, is an established regimen for the treatment of R/R AML. Peposertib is a …

us (code pays fourni par la source)

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Lindsay A. M. Rein, Firas El Chaer, Junichiro Yuda, Joseph Michael Scandura et autres

Abstract Background: PIM1 is overexpressed in hematologic malignancies, including myelofibrosis (MF), contributing to disease progression by modulating cytokine-driven pathways such as PI3K/AKT and JAK/STAT. Elevated pro-inflammatory cytokines are a hallmark of MF and are closely linked to symptom burden and poor prognosis. …

us, jp, it, gb, fr, au (code pays fourni par la source)

Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings

Mikkael Aaron Sekeres, Sangeetha Venugopal, Namrata S. Chandhok, Justin M. Watts et autres

Myelodysplastic syndromes (MDS) are hematopoietic stem cell malignancies that vary both in clinical presentation and risk of transformation to acute myeloid leukemia [1–3]. Lower-risk MDS (LR-MDS) ...

us (code pays fourni par la source)

Hypothermic Machine Perfusion Parameters Are Associated with Donor Characteristics and Post-Transplant Outcomes in Deceased Donor Kidney Transplant

Jennifer L. Philip, Alex H. Gifford, Deborah C. Rice, Terrence Bradley et autres

Purpose: Hypothermic machine perfusion (HMP) is widely used in deceased donor kidney transplants (DDKT). Currently, there is a limited understanding of how perfusion parameters of flow and resistant relate to donor characteristics and risk factors nor whether they predict post-transplant outcomes. The …

us (code pays fourni par la source)

Characterizing Immunosuppressive Regimes at Induction Associated with Colorectal Cancer Recurrence and Survival Rates

Alex H. Gifford, D. Meyer, Terrence Bradley, Brad C. Astor et autres

Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML

Justin M. Watts, Tiffany Nong, Katarina Micin, Deborah Soong et autres

Olutasidenib is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that was recently approved by the US FDA for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring mutant IDH1. In the pivotal Phase II trial …

us (code pays fourni par la source)